Mayne Pharma Group Limited Overview
Mayne Pharma is a small-cap specialty pharmaceutical company. It is listed in Australia, but its economic centre of gravity is the United States, where roughly 82% of revenue is generated.
Since FY22 it has been rebuilt from a debt-laden generics and contract-manufacturing conglomerate into a branded US women's-health and dermatology franchise. It is anchored by four women's-health brands:
-
NEXTSTELLIS®, an estetrol-based oral contraceptive
-
ANNOVERA®, a one-year vaginal ring
-
IMVEXXY®, a vaginal estradiol insert
-
BIJUVA®, an estradiol/progesterone capsule
These sit alongside a margin-focused dermatology portfolio and an Australian manufacturing and export arm at Salisbury.
Its newest strategic asset is DistributeRx. Launched in March 2026, it is a direct-to-patient, cash-pay prescription channel built on its Adelaide Apothecary mail-order pharmacy, and it is now open to third-party manufacturers.
FY26 revenue was A$383.7m at a 64.7% gross margin, with underlying EBITDA of A$34.2m. The company holds A$80.0m of cash against A$43.2m of interest-bearing debt. Large contingent earn-out liabilities (A$265.5m) linked to acquired brands are the main balance-sheet overhang.
Company's own description (FY26 Annual Report, paraphrased)
The company describes itself as an ASX-listed specialty pharmaceutical company that commercialises novel branded women's-health and dermatology medicines. Its stated aim is to offer patients better, safe and more accessible medicines.
It points to:
-
A 40-year record in oral drug-delivery technologies.
-
A Salisbury (South Australia) development and manufacturing facility with expertise in complex oral and topical dose forms, including modified-release products and poorly soluble compounds.
-
A contract development and manufacturing (CDMO) service for third parties.
Independent characterisation
Mayne Pharma is best understood as a US commercial-stage, in-licensing and acquisition-led branded pharma platform. It has an Australian manufacturing tail. It does not carry out early-stage drug discovery.
Its model has three parts:
-
Acquiring or licensing late-stage or already-approved US brands. Consideration is often heavily deferred through earn-outs and royalties.
-
Re-launching those brands through a focused US sales force of OB/GYN and dermatology representatives, supported by medical science liaisons.
-
Managing gross-to-net economics through channel strategy: specialty pharmacies, its own Adelaide Apothecary mail-order pharmacy, GoodRx-enabled cash prices, and now DistributeRx.
The Australian business manufactures and sells branded and generic products ex-US and provides CDMO services.
Revenue model mix
| Revenue line (AUD Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Sale of goods | 351.8 | 364.2 | 352.3 |
| Services revenue | 35.3 | 42.4 | 26.0 |
| Licence fee revenue | 0.2 | 0.4 | 0.0 |
| Royalties revenue | 1.1 | 1.2 | 5.3 |
| Total revenue | 388.4 | 408.1 | 383.7 |
Source: FY25 and FY26 Annual Reports, consolidated statement of profit or loss.
Mix in FY26:
-
Products: 91.8% of revenue.
-
Services: 6.8%, mainly distribution, pharmacy and contract-manufacturing related.
-
Royalties: 1.4%.
-
There is no subscription revenue.
-
Branded products were 83% of net sales in FY26, up from 79% in FY25. Generics were 17% (FY26 Annual Report).
Value-chain position
| Value-chain stage | Mayne role |
|---|---|
| Discovery / early R&D | Minimal. R&D expense is mainly post-marketing studies and lifecycle work (A$20.7m in FY26) |
| Late-stage development / regulatory | Selective: post-approval FDA studies for ANNOVERA® and IMVEXXY®; formulation work at Salisbury |
| Manufacturing | US brands are largely third-party manufactured. Salisbury makes Australian and export products and CDMO volumes |
| Commercialisation | Core competency: US field force and marketing for women's health; digital and channel-led dermatology |
| Distribution / dispensing | Increasingly vertical: Adelaide Apothecary (licensed US mail-order pharmacy) and DistributeRx (direct-to-patient platform) |
Customers and end-markets
Ultimate prescribers: - US OB/GYNs, women's-health nurse practitioners and primary care physicians.
-
US dermatologists, with 5,042 unique prescribers using DistributeRx since its March 2026 launch.
-
Australian GPs and specialists.
Paying and purchasing customers: - US wholesalers and specialty pharmacies (more than 400 in the dermatology channel network).
-
PBMs and payers, through rebates.
-
Patients paying cash through Adelaide Apothecary and DistributeRx.
-
Australian pharmacy wholesalers, with PBS reimbursement.
-
Export distributors, for example KADIAN® in Canada.
-
CDMO clients.
End-markets: - US contraception
-
US menopause and hormone therapy
-
US medical dermatology (acne, rosacea, psoriasis)
-
Australian prescription pharmaceuticals, including pain (opioids) and urology
-
Contract manufacturing
Strategy
Stated strategic priorities (FY26 Annual Report, paraphrased)
| Priority | Stated activities |
|---|---|
| Deliver the profit potential of the current Women's Health portfolio | Sharpen sales execution and targeted marketing for operating leverage; protect long-term asset value through IP management and Key Opinion Leader (KOL) education; evaluate complementary assets |
| Differentiate the channel to become the preferred solution for patients, prescribers and partners | Make channel processes easy to use; pursue capital-efficient, accretive dermatology business development; broaden the product range on the platform |
| Drive international profit through new revenue streams and modernisation | Use Salisbury capacity; targeted maintenance capex only; expand KAPANOL®/KADIAN® ex-Australia |
FY27 outlook themes (FY26 results)
Women's Health: accelerate growth through a focused sales force, refreshed marketing and better prescriber access. The tailwind is the removal of the HRT boxed warning, especially for BIJUVA®.
Dermatology / DistributeRx: scale the platform. Management expects some loss of insurance coverage for TWYNEO® and generic entry against RHOFADE®.
International: build on the NEXTSTELLIS® PBS listing; grow exports and CDMO revenue from the Salisbury investment.
Corporate: evaluate capital-efficient, synergistic acquisitions alongside disciplined capital management. Earlier (Feb 2026) the CEO also listed share repurchases as a capital-allocation option under evaluation.
Strategic initiatives register (last 24 months)
| Initiative | Date | Description | Target / status |
|---|---|---|---|
| Women's Health marketing refresh | FY25 | New marketing materials across all brands | Completed |
| TWYNEO® / EPSOLAY® acquisition and launch | Apr 2025; launched 1H FY26 | Two FDA-approved topical brands for US$16m | Launched; coverage risk in FY27 |
| Salisbury modernisation | FY23–Dec 2025 | A$18m upgrade (encapsulation, blister, bottling lines) | Completed; DIFOT 97.4% |
| NEXTSTELLIS® PBS listing | Effective 1 Oct 2025 | Reimbursed access in Australia | Demand cycles +127% in FY26 |
| Retention program | Dec 2025 | Cash and RSU retention awards; quarterly STI | RSUs vest Sep 2026 |
| Board and management renewal | Jan–Aug 2026 | Board cut to 5; new Chair, CEO and CFO; US commercial and shareholder-investor directors added | Completed |
| Women's Health field force expansion | 2H FY26 | National realignment; menopause and contraception specialists in metro markets | Ongoing; drove the EBITDA dip |
| DistributeRx launch | Mar 2026 | Direct-to-patient cash-pay platform, plus manufacturer services as a B2B revenue stream | 62k TRx in first full quarter; 7 manufacturers in discussion |
| Adelaide Apothecary relocation | Announced 18 May 2026 | Automated Lexington, KY facility; capacity above 2.5m prescriptions per year | Operations early 2027; Phase 1 up to US$2m |
| First third-party DistributeRx product | Jun 2026 | Exclusive US distribution of RECEDO® (Resilia) | Live |
| Tariff mitigation | 7 Apr 2026 | US Section 232 tariff assessment | No material impact expected |
| ANNOVERA® channel shift | FY26 | Move to channels with lower returns | Ongoing |
| Climate disclosure readiness | FY26–FY27 | Australian mandatory climate reporting (AASB S2) identified as a risk | Mandatory regime phase-in (see Section 20) |
Medium-term targets
No quantitative revenue, EBITDA or margin guidance has been issued for FY27 or beyond. The company gives qualitative outlook statements only. The only quantified operating target is the DistributeRx and Adelaide Apothecary capacity goal of more than 2.5m prescriptions a year.
Products & Services
Women's Health (US)
| Product | Description / specification | Target customer | Approval / launch | Pricing / commercial notes |
|---|---|---|---|---|
| NEXTSTELLIS® | Combined oral contraceptive: drospirenone 3 mg and estetrol (E4) 14.2 mg. The only US oral contraceptive containing estetrol, a plant-derived, body-identical estrogen. Orange Book patent protection to 2043 | OB/GYNs, women seeking a novel-estrogen pill | FDA approval Apr 2021; licensed from Mithra (2019) | FY26 US net sales US$45.2m (+6%); demand cycles +15%. Added about 15 million zero-copay covered lives in FY26 via new PBM relationships, with higher rebates. Earn-out / deferred consideration payable on US distribution rights |
| ANNOVERA® | Segesterone acetate / ethinyl estradiol vaginal system: a single ring providing one year (13 cycles) of contraception | Women seeking long-acting, user-controlled contraception | Licensed via TXMD (Dec 2022); originated by Population Council | FY26 net sales US$25.7m (-13%); TRx +2%. Persistent product returns, so the company shifted to channels with better returns profiles. FDA-required post-approval study ongoing. US$13m (A$20m) paid to Population Council in FY25 |
| IMVEXXY® | Estradiol vaginal inserts, 4 mcg and 10 mcg, for moderate-to-severe dyspareunia due to menopause | Post-menopausal women, OB/GYNs | Licensed via TXMD (Dec 2022) | FY26 net sales US$29.3m (+8%); TRx +6%. Patents expire 2032/2033. Paragraph IV challenges from Teva (2020) and Sun Pharma (Jun 2024). Post-approval study ongoing |
| BIJUVA® | Estradiol / progesterone capsules (1 mg/100 mg) for moderate-to-severe vasomotor symptoms of menopause in women with a uterus | Menopausal women, OB/GYNs | Licensed via TXMD (Dec 2022); boxed warning removed Feb 2026 | FY26 net sales US$15.0m (+20%); TRx +26%, the fastest-growing brand |
Dermatology (US)
| Product | Description | Indication / target | Status | Notes |
|---|---|---|---|---|
| gACCUTANE® (isotretinoin) | Oral retinoid | Severe recalcitrant nodular acne | Established | About 62% category share of new prescriptions at Q4 FY26, measured against a company-defined competitor set (IQVIA NRx) |
| DORYX® / DORYX MPC® | Delayed-release doxycycline hyclate | Acne (adjunct), infections | Established; Mayne trademark | Losing share amid competitor activity and branded oral-antibiotic decline |
| RHOFADE® | Oxymetazoline HCl cream 1% | Persistent facial erythema of rosacea | Established; Mayne trademark | US$37.8m net revenue in FY25 (+28%). Insurance coverage loss (FY25–26); generic launched Jul 2026, so share and volume loss expected |
| ORACEA® authorised generic | Doxycycline 40 mg modified-release | Rosacea (papulopustular) | Authorised generic | Competitive generic launches eroded FY25–26 revenue |
| TWYNEO® | Tretinoin 0.1% / benzoyl peroxide 3% cream (NDA 214902) | Acne vulgaris, ages 9 and over | US rights acquired Apr 2025; launched 1H FY26 | Expected loss of some insurance coverage in FY27. The FY26 Annual Report letter describes it as "tretinoin and ivermectin"; the FY25 Directors' Report and NDA description state tretinoin/benzoyl peroxide, which is taken as correct |
| EPSOLAY® | Benzoyl peroxide cream (microencapsulated) (NDA 214510) | Inflammatory lesions of rosacea, adults | US rights acquired Apr 2025; launched 1H FY26 | US$16m combined consideration for TWYNEO®/EPSOLAY® |
| FABIOR® | Tazarotene foam | Acne | Established; Mayne trademark | Detailed sales n/d |
| SORILUX® | Calcipotriene foam | Plaque psoriasis | Established; Mayne trademark | Detailed sales n/d |
| LEXETTE® | Halobetasol propionate foam | Plaque psoriasis | Established; Mayne trademark | Detailed sales n/d |
| Branded Retin-A® (tretinoin) cream | Topical retinoid | Acne | Launched 1H FY25 | Detailed sales n/d |
Channel platforms (US)
| Platform | Description | Launch | Metrics |
|---|---|---|---|
| Adelaide Apothecary | Licensed specialty mail-order pharmacy; fulfilment arm of DistributeRx. Relocating to an automated Lexington, Kentucky facility about 4 times its current footprint, with capacity over 2 phases exceeding 2.5m prescriptions per year (about 7 times current) | Existing (EBITDA breakeven FY25); new facility expected early 2027 | Up to US$2m capex for Phase 1 |
| DistributeRx | Direct-to-patient prescription channel: digital workflows, transparent cash-pay pricing and pharmacy fulfilment. Also offers manufacturer services (co-pay optimisation, fulfilment, direct-to-pharmacy contracting) | Mar 2026 | First full quarter (Q4 FY26): 62k TRx (+63% vs pcp) and 42k NRx (+104%); 5,042 unique prescribers. At 30 Jun 2026, in discussions with 7 manufacturers covering about 13 products (11 dermatology, 2 non-dermatology). President: Daniel Moore |
| RECEDO® (third-party) | Topical silicone gel for scar management (Resilia Pharmaceuticals); exclusive US distribution via DistributeRx | Jun 2026 | First third-party product on the platform |
International
| Product / service | Description | Market | Notes |
|---|---|---|---|
| KAPANOL® / KADIAN® | Modified-release morphine sulfate capsules (Mayne proprietary pellet technology) | Australia (KAPANOL®); Canada and export (KADIAN®) | Expanded Canadian distribution agreement (FY25). KAPANOL® 200 mg launched FY24 |
| Oxycodone products | Generic opioid analgesics | Australia | Cited as a strong domestic seller in FY25 |
| UROREC® | Silodosin | Australia (benign prostatic hyperplasia) | Cited as a strong domestic seller in FY25 |
| NEXTSTELLIS® (Australia) | Estetrol/drospirenone combined oral contraceptive | Australia | PBS listing from 1 Oct 2025. FY26 demand cycles +127%, and +188% since PBS listing. About 520,000 Australian women used a comparable combined pill in 2024 |
| CDMO services | Formulation development and manufacture of complex oral and topical dose forms (modified release, poorly soluble compounds) at Salisbury | Global clients | A$18m upgrade (A$4.8m Modern Manufacturing Initiative grant). DIFOT (delivered in full on time) 97.4% in FY26. Commercial discussions in Asian territories |
| Other generics / brands | More than 57 products marketed globally (FY25 Annual Report) | Australia and export | Individual product sales n/d |
Financial Narrative
Basis and sources:
-
FY22–FY23 figures are restated "continuing operations" (excluding Metrics and Retail Generics), as presented in later reports.
-
FY24–FY26 figures are from audited Annual Reports (FY25, FY26).
-
FY22–FY23 figures are from the FY23 AGM / FY24 results comparatives.
Income statement
Notes:
-
FY23 total NPAT of +A$117.2m includes a A$434.6m profit from discontinued operations, mainly the Metrics sale.
-
The FY26 Annual Report five-year table shows NPAT of -A$220.1m (FY22) and -A$317.4m (FY23) labelled as attributable to shareholders on a continuing basis.
-
FY22 gross profit and FY22–FY23 D&A were not disclosed on a comparable restated basis in the sources reviewed.
Per-share data (A$, post 20:1 consolidation)
Source: FY26 Annual Report remuneration report five-year table, and P&L. The FY23 A$0.54 was a capital distribution following asset sales.
Margins (%, analyst-computed)
Revenue CAGR:
-
FY22–FY26: (383.7/157.1)^(1/4) - 1 = about 25.0% a year. This reflects the FY24 step-change from the TXMD acquisition.
-
FY24–FY26: about -0.6% a year, essentially flat on a reported A$ basis.
Earnings quality: reported vs underlying, FY26
Source: FY25 and FY26 Annual Reports, reconciliation tables: FY26 statutory profitability is not operating profitability. The A$125.6m non-cash gain arises from writing down earn-out liabilities:
-
TXMD-related: about A$104.6–104.8m.
-
NEXTSTELLIS® US distribution rights: A$19.8m.
These write-downs reflect lower revenue forecasts for those products. Adjusted PBIT was -A$29.7m and adjusted PBT -A$71.4m.
Underlying EBITDA was also revised upward between the 31 Jul unaudited update (A$31.7m) and the audited release (A$34.2m). The A$2.5m change came from reclassifying retention-related share-based expense as a one-off adjustment.
Balance sheet
Notes:
-
FY22 net debt (A$317m) and FY23 net cash (A$172.6m) are company-reported (2024 AGM presentation).
-
The company reported FY24 net cash as A$107.6m. Analyst computation gives A$110.5m; the difference is definitional, likely lease treatment.
-
Interest-bearing debt is essentially the Dec 2022 convertible notes (carrying A$39.1m at Jun 2026, A$41.6m repayable at maturity if not converted) plus lease liabilities.
-
Earn-out liabilities are economically debt-like and far exceed the convertible notes. Including them, adjusted net debt at Jun 2026 is about A$228.7m.
-
Goodwill is not separately disclosed in the extracts reviewed.
Cash flow
Notes:
-
The FY26 media release uses A$34.5m as "operating cash flow from continuing operations before transaction and litigation costs". The Annual Report labels A$34.5m "adjusted".
-
FY26 investing inflow includes A$39.0m from redeeming marketable securities.
Ratios (analyst-computed)
Ratios not computed:
Net debt / EBITDA: net cash position, so not meaningful. Including earn-outs, about 6.7x underlying FY26 EBITDA.
Interest coverage: FY26 reported EBIT / other finance expense = A$77.5m / A$5.3m = 14.6x, but distorted by the earn-out gain. On underlying EBIT (negative) coverage is not meaningful.
Cash conversion cycle: not meaningful. Payables include large gross-to-net (rebate) accruals, and receivables are gross of rebates.
Commentary on trends, inflections and drivers
1. FY22–FY23: portfolio surgery.
The group sold Metrics (Oct 2022) and US Retail Generics (FY23), retired syndicated debt and returned capital. It swung from A$317m net debt (FY22) to A$172.6m net cash (FY23).
Continuing-operations P&L in this period was deeply loss-making:
-
Underlying EBITDA of -A$59.6m (FY22) and -A$95.3m (FY23).
-
Large intangible impairments: FY23 reported net loss included A$134.7m of depreciation, amortisation and impairment.
2. FY24 inflection.
Revenue more than doubled to A$388.4m with a full year of the TXMD brands. Underlying EBITDA turned positive (A$22.9m). Women's Health revenue rose 131% and Dermatology 207%, the latter on a gross-to-net reset and channel fixes. Statutory results were hit by:
-
A$82.7m of earn-out upward reassessments (higher forecasts, so higher liabilities).
-
A A$33.3m class action settlement.
3. FY25 peak of the turnaround.
-
Revenue +5% to A$408.1m; gross margin up to 60.6%; underlying EBITDA more than doubled to A$47.0m.
-
Adjusted operating cash flow of A$45.4m.
-
Supporting items: a A$13.2m US tax refund, and a roughly A$5.6m managed-care accrual true-up that flattered EBITDA.
4. FY26 setback with mix improvement.
Revenue fell 6%, driven by:
-
Foreign exchange: AUD/USD moved from 0.6529 to 0.6894 at year end; about A$1.9m EBITDA impact.
-
Dermatology erosion.
Underlying EBITDA fell 27%, driven by:
-
About A$7.1m of short-term incentives reinstated (nil in FY25).
-
Absence of the FY25 A$5.6m true-up.
-
A 2H step-up in Women's Health promotion.
-
Post-marketing study costs.
-
Cosette-related disruption.
Gross margin nevertheless expanded for a third straight year, to 64.7%. Statutory profit turned positive only through the A$125.6m earn-out gain.
5. Cash trajectory.
Cash and securities fell from A$149.3m (FY24) to A$100.4m (FY25) to A$80.0m (FY26). Earn-out payments (A$21.8m, A$39.8m, A$25.7m) and Cosette legal costs absorbed most organic cash generation. Sustained free cash flow after earn-outs has not yet been demonstrated.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement
| Metric (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (continuing) | 157.1 | 183.6 | 388.4 | 408.1 | 383.7 |
Gross profit | — | 83.5 | 218.8 | 247.3 | 248.1 |
Underlying (adjusted) EBITDA | -59.6 | -95.3 | 22.9 | 47.0 | 34.2 |
Reported EBITDA (continuing) | 9.0 | -102.0 | -92.5 | 18.4 | 141.4 |
Depreciation and amortisation | — | — | 68.5 | 69.3 | 63.7 |
Reported EBIT (continuing) | — | — | -161.0 | -50.9 | 77.5 |
Pre-tax profit (continuing) | — | -269.7 | -190.1 | -83.3 | 35.8 |
NPAT continuing operations | -220.1 | -317.4 | -168.6 | -90.1 | 31.2 |
NPAT total (incl. discontinued) | — | 117.2 | -174.2 | -93.8 | 24.5 |
Research, development, medical and regulatory expense | — | — | 20.2 | 17.9 | 20.7 |
Marketing and distribution expense | — | — | 130.7 | 136.8 | 139.6 |
Per share (AUD)
| Per share (AUD) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Basic EPS (total) | -2.55 | -3.86 | -2.19 | -1.19 | 0.31 |
Diluted EPS (total) | — | — | -2.19 | -1.19 | 0.21 |
Basic EPS (continuing) | — | — | -2.12 | -1.14 | 0.39 |
Dividends / capital return per share | 0 | 0.54 | 0 | 0 | 0 |
Margin (%)
| Margin (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin | — | 45.5 | 56.3 | 60.6 | 64.7 |
Underlying EBITDA margin | -37.9 | -51.9 | 5.9 | 11.5 | 8.9 |
Reported EBITDA margin | 5.7 | -55.6 | -23.8 | 4.5 | 36.9 |
Reported EBIT (operating) margin | — | — | -41.5 | -12.5 | 20.2 |
Net margin (continuing NPAT) | -140.1 | -172.9 | -43.4 | -22.1 | 8.1 |
Income Statement (FY2025–FY2026)
| Bridge item (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Reported EBITDA | 18.4 | 141.4 |
Earn-out reassessments (gain negative) | 16.6 | -125.6 |
Restructuring incl. retention awards | 1.6 | 7.2 |
Diligence, transaction and Cosette litigation (net of recoveries) | 8.5 | 11.8 |
Convertible-note derivative fair-value change | -1.7 | -7.3 |
Women's Health supplier support | 0 | 1.4 |
Drug-pricing / DOJ-related litigation | 3.5 | 5.3 |
Underlying EBITDA | 47.0 | 34.2 |
Balance Sheet
| Metric (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets | — | — | 1,143.2 | 1,014.6 | 909.4 |
Cash and equivalents | — | — | 110.1 | 59.8 | 80.0 |
Marketable securities | — | — | 39.2 | 40.6 | 0.0 |
Trade and other receivables | — | — | 193.2 | 180.6 | 174.6 |
Inventories | — | — | 74.6 | 50.6 | 55.5 |
Intangible assets (incl. goodwill) | — | — | 568.6 | 545.8 | 463.1 |
Interest-bearing debt, current (incl. leases) | — | — | 35.5 | 38.6 | 41.6 |
Interest-bearing debt, non-current (incl. leases) | — | — | 3.4 | 2.7 | 1.6 |
Total interest-bearing debt | — | — | 38.8 | 41.3 | 43.2 |
Other financial liabilities (earn-outs / deferred consideration) | — | — | 381.8 | 409.1 | 265.5 |
Trade and other payables | — | — | 244.5 | 174.3 | 194.0 |
Total liabilities | — | — | 689.0 | 644.3 | 518.5 |
Total equity | — | 634.4 | 454.2 | 370.3 | 390.9 |
Total current assets | — | — | 460.6 | 352.8 | 339.5 |
Total current liabilities | — | — | 345.6 | 261.0 | 259.9 |
Working capital (current assets less current liabilities) | — | — | 115.0 | 91.8 | 79.5 |
Net debt (positive = net debt; debt less cash and marketable securities) | 317.0 | -172.6 | -110.5 | -59.1 | -36.8 |
Cash Flow
| Metric (AUD Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Net operating cash flow (statutory, total) | -15.3 | 17.5 | 13.9 |
Operating cash flow, continuing (company estimate) | 8.1 | 25.4 | 24.9 |
Adjusted operating cash flow, continuing (ex class action, tax refund, Cosette costs) | 8.1 | 45.4 | 34.5 |
Capex: property, plant and equipment (net of grant) | 8.0 | 11.1 | 2.9 |
Payments for intangibles and capitalised development | 12.9 | 16.7 | 0.4 |
Free cash flow (statutory OCF less capex and intangibles) | -36.2 | -10.3 | 10.6 |
Earn-out and deferred settlement payments | 21.8 | 39.8 | 25.7 |
Free cash flow after earn-out payments | -58.0 | -50.1 | -15.1 |
Dividends paid | 0 | 0 | 0 |
Share buy-backs | 10.9 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
ROE % (total NPAT / average equity) | -32.0 | -22.8 | 6.4 |
ROA % (total NPAT / average assets; FY24 on year-end assets) | -15.2 | -8.7 | 2.5 |
ROIC % (underlying EBIT x 0.7 / (equity + interest-bearing debt)) | -6.5 | -3.8 | -4.8 |
Current ratio (x) | 1.33 | 1.35 | 1.31 |
Debt / equity (x, interest-bearing only) | 0.09 | 0.11 | 0.11 |
Debt incl. earn-outs / equity (x) | 0.93 | 1.22 | 0.79 |
Asset turnover (x) | 0.34 | 0.38 | 0.40 |
DSO (days, receivables / revenue x 365) | 182 | 162 | 166 |
DIO (days, inventory / cost of sales x 365) | 161 | 115 | 149 |
Geographic revenue (AUD Mn, segment proxy)
| Geographic revenue (AUD Mn, segment proxy) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
United States (Women's Health + Dermatology) | 317.7 | 332.5 | 313.0 |
Australia and rest of world (International) | 70.7 | 75.6 | 70.7 |
Total | 388.4 | 408.1 | 383.7 |
Geographic share and growth (%)
| Geographic share and growth (%) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
US share of revenue | 81.8 | 81.5 | 81.6 |
Ex-US share of revenue | 18.2 | 18.5 | 18.4 |
US revenue growth (AUD) | — | 4.7 | -5.9 |
Ex-US revenue growth (AUD) | — | 6.9 | -6.5 |
Share price (AUD)
| Share price (AUD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
30 June close | 6.40 | 5.00 | 4.40 | 4.71 | 5.00 | 2.79 |
Performance to 30 Jun 2026 Details
| Performance to 30 Jun 2026 (%) | 1-year | 3-year | 5-year |
|---|---|---|---|
Price return | -44.2 | -36.6 | -56.4 |
Valuation Multiples
| Multiple | Mayne (ex earn-outs) | Mayne (incl. earn-outs) |
|---|---|---|
P/E (FY26 reported NPAT A$24.5m) | about 10.4x (distorted by A$125.6m non-cash gain) | — |
P/E (underlying) | not meaningful (underlying loss) | — |
EV / underlying EBITDA (FY26 A$34.2m) | about 6.4x | about 14.2x |
EV / Sales (FY26 A$383.7m) | about 0.57x | about 1.26x |
P/B (equity A$390.9m) | about 0.65x | — |
Capital Markets
| Item | Detail |
|---|---|
Credit ratings (Moody's / S&P / Fitch) | None; unrated |
Convertible notes | Issued Dec 2022 to fund the TXMD licence. Carrying value A$39.1m (Jun 2026); A$41.6m repayable at maturity if not converted. Classified as current. Exact maturity date n/d in extracts reviewed. Embedded derivative fair-value gain of A$7.3m in FY26 |
Lease liabilities | About A$4.1m (derived: A$43.2m total less A$39.1m notes) |
Bank debt | None (syndicated facility repaid post-FY23) |
Contingent consideration | A$265.5m (current A$13.9m; non-current A$251.6m), mainly the TXMD earn-out / deferred consideration and NEXTSTELLIS® distribution rights |
Analyst Conclusions
Management guidance
There is no numerical FY27 guidance. The qualitative priorities are:
-
Accelerate Women's Health, especially menopause.
-
Scale DistributeRx, including third-party products and the Lexington facility from early 2027.
-
Absorb RHOFADE® generic and TWYNEO® coverage headwinds.
-
Grow NEXTSTELLIS® in Australia and Salisbury exports and CDMO.
-
Pursue capital-efficient bolt-on M&A.
Consensus growth expectations: not publicly available (no major broker coverage).
Bull case
-
Menopause re-rating is under way. BIJUVA® TRx +26% and IMVEXXY® TRx +6% in FY26, before a full year of boxed-warning removal. A low single-digit share of a US$15–25bn market leaves room to grow, and Women's Health gross margin is 79%.
-
DistributeRx could become a capital-light second engine. The first full quarter delivered 62k TRx, 104% NRx growth and 5,042 prescribers, with seven manufacturers in the pipeline. Third-party fees would diversify away from Mayne's own maturing dermatology brands.
-
Hidden asset value. The stock trades near 0.65x book and about 6.4x EV/underlying EBITDA. Mayne has A$80m cash and a live damages claim against a PE-backed bidder that agreed to pay A$7.40 a share, plus the Takeovers Panel and first-instance findings in its favour.
Bear case
-
The operating trend is negative. Underlying EBITDA fell 27% in FY26 and Q4 EBITDA was only A$4.6m. Generic RHOFADE® and TWYNEO® coverage losses will hit FY27 dermatology revenue, and DistributeRx may not offset them before the Lexington site opens in 2027.
-
Statutory profit masks deteriorating forecasts. The A$125.6m earn-out reversal shows management cut revenue expectations for the TXMD brands and NEXTSTELLIS®. A$265.5m of contingent liabilities remain, and free cash flow after earn-outs has been negative for three years.
-
Litigation can cut both ways. A successful Cosette appeal would undermine the damages claim and could revive misleading-conduct allegations. The TXMD disputes, IMVEXXY® Paragraph IV cases and DOJ matters add cost (more than A$17m of litigation and transaction expense in FY26 before recoveries) and distraction.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
| NSW Court of Appeal decision on Cosette appeal | Any time (reserved since Jun 2026) | Determines leverage in the damages suit |
| Progress / settlement of damages claim vs Cosette, Avista and Burgstahler | FY27 | Potentially transformational cash recovery |
| Q1 FY27 quarterly update | About late Oct 2026 | First read on RHOFADE® generic impact and BIJUVA® trajectory |
| 2026 AGM | About Nov 2026 (date n/d) | Board endorsement of new directors; capital-management signals |
| 1H FY27 results | About late Feb 2027 | EBITDA recovery test |
| Lexington, KY facility start-up | Early 2027 | DistributeRx capacity |
| Additional third-party DistributeRx signings | Ongoing | Platform validation |
| IMVEXXY® Paragraph IV developments | Ongoing | Patent life to 2032–2033 at risk |
| TXMD Delaware litigation / dispute resolution | Ongoing | Contingent liability |
| Convertible note maturity / conversion | Within 12 months (classified current) | About A$41.6m cash call if not converted |
| Funicular Funds / board-led capital-allocation actions (buy-back, M&A, strategic review) | FY27 | Shareholder-value unlock |
| First mandatory climate-related financial disclosures | FY27 reporting | Compliance |
Analyst verdict
Mayne Pharma enters FY27 as a company whose intrinsic franchise quality has improved while its reported trajectory has worsened.
What is going right. The portfolio surgery of FY22–FY24 worked. A loss-making generics conglomerate with A$317m of net debt became a focused US branded business with a 64.7% gross margin, no bank debt and A$80m of cash. The menopause assets now have a real regulatory tailwind. NEXTSTELLIS® retains a long patent runway. DistributeRx is a credible, if early, answer to the collapse of branded-dermatology economics.
What went wrong. FY26 exposed the fragility beneath. Underlying EBITDA fell to A$34.2m and the fourth quarter almost broke even at the EBITDA line. Statutory profit was produced only by writing down earn-out liabilities, which is an admission that acquired-brand forecasts were too optimistic. Contingent consideration of A$265.5m still absorbs most of the free cash flow the business generates. The failed Cosette transaction consumed a year of management bandwidth, triggered wholesale leadership turnover and left the register with event-driven holders rather than long-only institutions.
How the equity is priced. At around A$2.5–3.2 a share, the market capitalises Mayne at roughly a third to two-fifths of the A$7.40 scheme price. That valuation sits near book value, at a mid-single-digit multiple of trough EBITDA excluding earn-outs. The equity is effectively a call option on three things:
-
A favourable Court of Appeal outcome and meaningful damages recovery.
-
Menopause-led Women's Health growth outrunning dermatology erosion.
-
DistributeRx reaching third-party scale once the Lexington facility opens.
Balance of probabilities. The balance sheet gives the company time, and the damages claim supplies asymmetric upside. Operating proof points are lacking, however: positive free cash flow after earn-outs and stabilising group revenue in US-dollar terms. Until they appear, a cautious, catalyst-driven stance is warranted rather than a fundamental re-rating thesis.
Bottom line: speculative value with binary legal catalysts. Two signals to watch most closely are the reserved appeal judgment and the 1H FY27 EBITDA print.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / background | Education / age |
|---|---|---|---|---|
Aaron Gray | Chief Executive Officer | CEO since 20 Feb 2026; CFO Aug 2022–Feb 2026; joined Jul 2022 | Led the financial turnaround and margin program; central to the Cosette process and DistributeRx development | Age n/d |
Griffin D. Buchanan | Chief Financial Officer | From 1 Aug 2026 | Senior finance executive with global medtech and healthcare (women's health) experience | — |
Daniel Moore | President, DistributeRx | 2,026 | Formerly General Manager, Dermatology; more than 20 years in healthcare commercial roles | — |
Laura Loftus | Company Secretary | Since Mar 2020; with Mayne since May 2014 | Former solicitor, DLA Piper | BCom, LLB (Hons), Monash; GAICD |
Dr Tom Duthy | Investor Relations | Current | IR contact | — |
Directors' Remuneration
| Executive | Salary | STI | Termination | Other benefits | Super | Deferred STI | LTI / RSUs | Total FY26 | Total FY25 |
|---|---|---|---|---|---|---|---|---|---|
Aaron Gray (CEO, formerly CFO) | 1,050,781 | 265,904 | 0 | 29,301 | 12,306 | 14,077 | 905,875 | 2,279,245 | 1,218,983 |
Shawn O'Brien (former CEO) | 907,359 | 345,656 | 663,423 | 245,882 | 17,739 | 11,679 | 527,598 | 2,719,337 | 2,129,807 |
Board of Directors
| Director | Role | Appointed | Age | Background | Committees | FY26 fees (AUD) |
|---|---|---|---|---|---|---|
Prof Bruce Robinson AC | Independent Chair (from 14 Jan 2026) | 26 Aug 2014 | 70 | Endocrinologist; former Dean, Sydney Medical School; NED of Cochlear, Lorica, QBiotics; Chair of NHMRC | Audit & Risk (member); Nomination (Chair) | 222,619 |
Ann Custin | Independent NED | 23 Mar 2022 | 66 | Former Board Director and CFO, Siemens Medical Solutions; former CEO of Draeger Medical Systems (USA); NED of Establishment Labs | Audit & Risk (Chair); Remuneration & People (Chair); Nomination | 208,657 |
David Petrie | NED | 1 Sep 2022 | 60 | Principal, Stratford Advisory; 23 years at Merrill Lynch / BofA (Head of IB Melbourne) | Audit & Risk; Remuneration & People; Nomination | 194,440 |
Meghan Rivera | Independent NED | 26 Jun 2026 | 47 | VP & Global Commercial Lead, ViiV Healthcare; former US Market President, Organon; former SVP Women's Health, AMAG | Remuneration & People; Nomination | nil in FY26 |
Jacob Ma-Weaver | NED (shareholder nominee profile) | 14 Aug 2026 | 39 | Founder and Managing Member, Cable Car Capital (general partner of Funicular Funds, 9.90% holder); former board member of ARCA biopharma; Amici Capital, Dodge & Cox, McKinsey | — | — |
Major Shareholders
| Holder | Shares | % |
|---|---|---|
Funicular Funds LP (Cable Car Capital) | 8,045,349 | 9.90 |
Bruce Mathieson | 5,292,066 | 6.51 |
Rubric Capital Management LP | 4,356,426 | 5.36 |
Trium Capital LLP | 4,086,243 | 5.02 |
Citicorp Nominees | 8,310,352 | 10.23 |
BNP Paribas Nominees (IB Au Noms Retail) | 7,932,142 | 9.76 |
HSBC Custody Nominees A/C 2 | 5,409,304 | 6.66 |
BMG B J MYX Pty Ltd (Mathieson-related) | 5,183,477 | 6.38 |
HSBC Custody Nominees (GSCO Customers) | 4,457,159 | 5.49 |
BNP Paribas Nominees (Cowen and Co LLC) | 2,406,601 | 2.96 |
HSBC Custody Nominees | 2,298,086 | 2.83 |
Warbont Nominees | 2,014,093 | 2.48 |
BNP Paribas Noms | 1,496,245 | 1.84 |
Dr Kenney Wan | 1,355,391 | 1.67 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Competing products / positioning |
|---|---|---|
Women's Health: contraception | Organon & Co. | Broad women's-health franchise (contraceptives, Nexplanon implant) |
Women's Health: contraception | AbbVie | Lo Loestrin Fe (branded combined oral contraceptive) |
Women's Health: contraception | Bayer | Yaz/Yasmin family (drospirenone COCs), IUS products |
Women's Health: contraception | Exeltis (Insud Pharma), incl. ex-Agile Therapeutics | Slynd (progestin-only pill), Twirla patch |
Women's Health: contraception | Generic COC manufacturers (Lupin, Glenmark, Xiromed, others) | Low-cost generic pills, the main price competition |
Women's Health: menopause | Pfizer | Premarin / Prempro / Premarin Vaginal Cream |
Women's Health: menopause | Astellas | Veozah (fezolinetant), a non-hormonal VMS treatment |
Women's Health: menopause | Bayer | Non-hormonal elinzanetant (VMS) |
Women's Health: menopause / sexual health | Cosette Pharmaceuticals | Intrarosa, Vyleesi, Clomid; now a direct adversary in litigation |
Women's Health: vaginal estrogen generics | Teva, Sun Pharma (ANDA filers vs IMVEXXY®) | Potential generic entry |
Dermatology | Galderma | Market leader in aesthetics and dermatology (rosacea and acne brands) |
Dermatology | Bausch Health (Ortho Dermatologics) | Acne and psoriasis topicals |
Dermatology | Sun Pharma (US specialty derm) | Branded and generic dermatology |
Dermatology | Journey Medical | Small-cap US derm (incl. a rosacea minocycline product) |
Dermatology | Almirall, Verrica, generic topical makers | Niche brands and generics |
Direct-to-patient channel | GoodRx, Mark Cuban Cost Plus Drugs, BlinkRx, Amazon Pharmacy, manufacturer DTC portals | Cash-pay and digital pharmacy |
International (Australia) | Viatris, Sandoz, Arrotex, Apotex; CDMOs such as Catalent and Lonza | Generics and contract manufacturing |
Peer Comparison FY2026
| Metric | Mayne Pharma (FY26) | Organon (CY2024) | Galderma (CY2024) | Journey Medical (CY2024) |
|---|---|---|---|---|
Revenue | A$383.7m (about US$260m) | about US$6.4bn | about US$4.4bn | about US$56m |
Revenue growth | -6% (A$); about flat in US$ | about +1% | about +9% | about -29% |
Gross margin | 64.7% | — | — | — |
R&D intensity | 5.4% | — | — | — |
Profitability | Underlying EBITDA margin 8.9% | — | — | — |
Recent Developments
--



